Wu Chun-ping, Zhou Liang, Xie Ming, Tao Lei, Zhang Ming, Tian Jie
Department of Otorhinolaryngology Head and Neck Surgery, Fudan University Affiliated Eye, Ear, Nose and Throat Hospital, Shanghai 200031, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Mar;47(3):223-7.
To investigate a valuable strategy for further purifying cancer stem cells (CSCs) from laryngeal cancer cell line.
CD133+ side population (SP) and CD133-SP cells were detected and isolated from laryngeal cancer Hep-2 cell line with SP discrimination and CD133 surface marker, assisted by fluorescence activated cell sorting technology. Freshly sorted CD133+SP and CD133-SP cells were xenografted into the subcutaneous space of the right axillary fossa of NOD/SCID mice and tumorigenic capacity of the cells from two subgroups were examine. Cell cycle distributions of the two cell populations were detected.
CD133+SP and CD133-SP cells accounted for (0.30±0.12)% and (17.52±1.59)% in Hep-2 cell line, respectively. CD133+SP cells formed tumor nodules in 15 of 16 mice and CD133-SP cells in 7 of 16 mice (Fisher's exact test, P<0.05). The mean weight of CD133+SP tumor nodules was (0.36±0.15)g and that of CD133-SP tumor nodules was (0.08±0.04) g. The difference was significant (t=4.64, P<0.01). Cell cycle analysis revealed similar cycle distributions between the two subgroups.
CD133+SP cells harbored much more cancer stem-like tumorigenic potential in NOD/SCID mice than CD133-SP cells. The combination of SP discrimination and surface marker selection helped to purify CSCs further from laryngeal cancer cell line.
探讨从喉癌细胞系中进一步纯化癌症干细胞（CSCs）的有效策略。
采用荧光激活细胞分选技术，借助SP分选和CD133表面标志物，从喉癌Hep-2细胞系中检测并分离CD133+侧群（SP）细胞和CD133-SP细胞。将新鲜分选的CD133+SP细胞和CD133-SP细胞接种到NOD/SCID小鼠右腋窝皮下，检测两组细胞的致瘤能力。检测两个细胞群体的细胞周期分布。
在Hep-2细胞系中，CD133+SP细胞和CD133-SP细胞分别占（0.30±0.12）%和（17.52±1.59）%。16只小鼠中有15只接种CD133+SP细胞后形成肿瘤结节，16只小鼠中有7只接种CD133-SP细胞后形成肿瘤结节（Fisher精确检验，P<0.05）。CD133+SP肿瘤结节的平均重量为（0.36±0.15）g，CD133-SP肿瘤结节的平均重量为（0.08±0.04）g。差异有统计学意义（t=4.64，P<0.01）。细胞周期分析显示两个亚组之间的周期分布相似。
在NOD/SCID小鼠中，CD133+SP细胞比CD133-SP细胞具有更强的癌症干细胞样致瘤潜能。SP分选和表面标志物选择相结合有助于从喉癌细胞系中进一步纯化CSCs。
